Treatment Resistant Depression / Propofol · Phase 2/3 Trial

Neural and Antidepressant Effects of Propofol

ClinicalTrials.gov · September 9, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a completed Phase 2/3 registry record for a randomized trial of propofol at two doses in treatment-resistant depression. No results have been posted to the registry, so no efficacy, safety, or biomarker findings can be evaluated from this source.

What was studied

Phase 2/3, Interventional, Randomized, Crossover, Quadruple masking, Treatment purpose. Treatment Resistant Depression; age from 18 Years; to 55 Years. Intervention: Propofol High Dose; Propofol Low Dose. Compared with: Propofol at different dose level (within-subject or between-arm comparison not clarified in registry record). n = 32. 1 site: United States.

Key findings

Safety

Results are not posted in this registry record; no efficacy, safety, or biomarker outcomes are reported.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

A small Phase 2/3 trial in treatment-resistant depression with completed enrollment but no posted results; the registry record alone cannot support any claim about efficacy or safety.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Hamilton Depression Rating Scale (assessed at approximately 17 days after randomization)

DesignPhase 2/3, Interventional, Randomized, Crossover, Quadruple masking, Treatment purpose

PopulationTreatment Resistant Depression; age from 18 Years; to 55 Years

Sample size32

InterventionPropofol High Dose; Propofol Low Dose

ComparatorPropofol at different dose level (within-subject or between-arm comparison not clarified in registry record)

Setting1 site: United States

Reported figures

Quoted from the source exactly as published.

Planned enrollment32

Primary outcome measureHamilton Depression Rating Scale

Primary assessment timepointapproximately 17 days after randomization

Study phasePhase 2, Phase 3

Recruitment statusCompleted

Caveats

Results are not posted in this registry record; no efficacy, safety, or biomarker outcomes are reported.
Randomization and blinding methodology are not described in the registry record.
No comparative effect sizes, confidence intervals, or p-values are available.
The study's findings remain unknown to the reader; this record is a placeholder for a study whose outcomes have not yet been disclosed.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Randomized interventional trial, phase 2/3, but results not yet reported in registry.

Directness

strong

Direct measurement of depression severity via Hamilton Depression Rating Scale at defined timepoint.

Consistency

insufficient

No results posted; consistency cannot be assessed from registry record alone.

Risk of bias

insufficient

Randomization and blinding status not stated in registry record; no outcome data available.

Sample adequacy

limited

32 participants total for a two-dose comparison study is a small sample.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT03684447). This is a study registration, not published results. Lead sponsor: University of Utah. Recruitment status: COMPLETED. Phase: PHASE2, PHASE3. Study type: INTERVENTIONAL. Enrollment: 32 participants (ACTUAL). Conditions: Treatment Resistant Depression. Interventions: DRUG: Propofol; DRUG: Propofol. Primary outcome measures: Hamilton Depression Rating Scale , approximately 17 days after randomization. Brief summary: This study will compare the antidepressant effects of propofol at two different doses while measuring potential treatment-related biomarkers.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Treatment Resistant DepressionUniversity of UtahPropofolNCT03684447